JP2018537400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537400A5 JP2018537400A5 JP2018511202A JP2018511202A JP2018537400A5 JP 2018537400 A5 JP2018537400 A5 JP 2018537400A5 JP 2018511202 A JP2018511202 A JP 2018511202A JP 2018511202 A JP2018511202 A JP 2018511202A JP 2018537400 A5 JP2018537400 A5 JP 2018537400A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- nos
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 1025
- 239000000427 antigen Substances 0.000 claims description 196
- 102000036639 antigens Human genes 0.000 claims description 196
- 108091007433 antigens Proteins 0.000 claims description 196
- 239000012634 fragment Substances 0.000 claims description 180
- 238000006467 substitution reaction Methods 0.000 claims description 53
- 238000007792 addition Methods 0.000 claims description 48
- 238000012217 deletion Methods 0.000 claims description 48
- 230000037430 deletion Effects 0.000 claims description 48
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 17
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 15
- 230000001404 mediated effect Effects 0.000 claims description 12
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 11
- 208000026278 immune system disease Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102000043131 MHC class II family Human genes 0.000 claims description 4
- 108091054438 MHC class II family Proteins 0.000 claims description 4
- 230000006044 T cell activation Effects 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 229940056913 eftilagimod alfa Drugs 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000006386 Bone Resorption Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 230000001270 agonistic effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 2
- 230000024279 bone resorption Effects 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000020694 gallbladder disease Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 210000003780 hair follicle Anatomy 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 208000000509 infertility Diseases 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 231100000535 infertility Toxicity 0.000 claims description 2
- 208000023589 ischemic disease Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000011475 meningoencephalitis Diseases 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 230000006052 T cell proliferation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021041608A JP2021097706A (ja) | 2015-09-02 | 2021-03-15 | 抗ｌａｇ−３抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1515572.4A GB201515572D0 (en) | 2015-09-02 | 2015-09-02 | Anti-LAG-3 antibodies |
| GB1515572.4 | 2015-09-02 | ||
| GB1612437.2 | 2016-07-18 | ||
| GBGB1612437.2A GB201612437D0 (en) | 2016-07-18 | 2016-07-18 | Anti-lag-3 antibodies |
| PCT/EP2016/070664 WO2017037203A1 (en) | 2015-09-02 | 2016-09-01 | Anti-LAG-3 Antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021041608A Division JP2021097706A (ja) | 2015-09-02 | 2021-03-15 | 抗ｌａｇ−３抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537400A JP2018537400A (ja) | 2018-12-20 |
| JP2018537400A5 true JP2018537400A5 (enExample) | 2019-10-17 |
| JP7074341B2 JP7074341B2 (ja) | 2022-05-24 |
Family
ID=56852278
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511202A Active JP7074341B2 (ja) | 2015-09-02 | 2016-09-01 | 抗ｌａｇ－３抗体 |
| JP2021041608A Pending JP2021097706A (ja) | 2015-09-02 | 2021-03-15 | 抗ｌａｇ−３抗体 |
| JP2022113055A Withdrawn JP2022137218A (ja) | 2015-09-02 | 2022-07-14 | 抗ｌａｇ－３抗体 |
| JP2024092967A Pending JP2024116273A (ja) | 2015-09-02 | 2024-06-07 | 抗ｌａｇ－３抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021041608A Pending JP2021097706A (ja) | 2015-09-02 | 2021-03-15 | 抗ｌａｇ−３抗体 |
| JP2022113055A Withdrawn JP2022137218A (ja) | 2015-09-02 | 2022-07-14 | 抗ｌａｇ－３抗体 |
| JP2024092967A Pending JP2024116273A (ja) | 2015-09-02 | 2024-06-07 | 抗ｌａｇ－３抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11680104B2 (enExample) |
| EP (2) | EP3344654B1 (enExample) |
| JP (4) | JP7074341B2 (enExample) |
| KR (2) | KR20250073532A (enExample) |
| CN (2) | CN108699145A (enExample) |
| AU (2) | AU2016316730B2 (enExample) |
| CA (1) | CA2995639A1 (enExample) |
| DK (1) | DK3344654T3 (enExample) |
| ES (1) | ES2842306T3 (enExample) |
| IL (1) | IL257798B2 (enExample) |
| MX (2) | MX2018002610A (enExample) |
| MY (1) | MY205096A (enExample) |
| NZ (1) | NZ779096A (enExample) |
| PH (1) | PH12018500369A1 (enExample) |
| PL (1) | PL3344654T3 (enExample) |
| PT (1) | PT3344654T (enExample) |
| RU (2) | RU2021133819A (enExample) |
| SG (1) | SG10201913864RA (enExample) |
| WO (1) | WO2017037203A1 (enExample) |
| ZA (1) | ZA201801432B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| CN108699145A (zh) * | 2015-09-02 | 2018-10-23 | 伊缪泰普有限公司 | 抗lag-3抗体 |
| PE20180773A1 (es) | 2015-10-02 | 2018-05-07 | Hoffmann La Roche | Anticuerpos biespecificos para pd1 y tim3 |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| PT3606946T (pt) | 2017-04-03 | 2022-10-17 | Hoffmann La Roche | Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15 |
| LT3606954T (lt) * | 2017-04-05 | 2022-09-26 | F. Hoffmann-La Roche Ag | Anti-lag3 antikūnai |
| CN116375876A (zh) | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
| NZ759517A (en) * | 2017-04-27 | 2025-02-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
| EP3675898A4 (en) * | 2017-08-30 | 2021-09-01 | Phanes Therapeutics, Inc. | ANTI-LAG-3 ANTIBODIES AND THEIR USES |
| BR112020011664A2 (pt) * | 2017-12-22 | 2020-11-17 | Jiangsu Hengrui Medicine Co., Ltd. | composição farmacêutica do anticorpo lag-3 e seu uso |
| WO2019129137A1 (zh) * | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| US11661452B2 (en) | 2018-03-20 | 2023-05-30 | WuXi Biologics Ireland Limited | Anti-lag-3 antibody polypeptide |
| WO2019186559A1 (en) * | 2018-03-27 | 2019-10-03 | Raz Yirmiya | Microglia modulators for use in treatment of depression |
| CN110343178B (zh) * | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | 抗人lag-3单克隆抗体及其应用 |
| CN110606892B (zh) * | 2018-06-14 | 2023-09-26 | 华博生物医药技术（上海）有限公司 | 一种高亲和力高生物活性的lag-3抗体及其应用 |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| CN111620949A (zh) * | 2019-02-28 | 2020-09-04 | 三生国健药业（上海）股份有限公司 | 结合人lag-3的抗体、其制备方法和用途 |
| GB201906118D0 (en) | 2019-05-01 | 2019-06-12 | Immutep S A | Anti-LAG-3 binding molecules |
| GB201906127D0 (en) | 2019-05-01 | 2019-06-12 | Immutep S A | Assays |
| PH12021552675A1 (en) | 2019-05-13 | 2022-07-04 | Regeneron Pharma | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| US20220227887A1 (en) * | 2019-06-11 | 2022-07-21 | Ono Pharmaceutical Co., Ltd. | Immunosuppressant |
| CN115666648A (zh) * | 2020-04-03 | 2023-01-31 | 索伦托药业有限公司 | 结合lag3的工程化抗体 |
| EP4157879A4 (en) | 2020-05-27 | 2024-06-19 | Agilent Technologies, Inc. | Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc) |
| CN116194480A (zh) | 2020-08-13 | 2023-05-30 | 百时美施贵宝公司 | 将il-2重定向到目的靶细胞的方法 |
| CN115819585B (zh) * | 2020-12-10 | 2023-06-02 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
| WO2024163477A1 (en) | 2023-01-31 | 2024-08-08 | University Of Rochester | Immune checkpoint blockade therapy for treating staphylococcus aureus infections |
| KR20250155054A (ko) | 2023-03-13 | 2025-10-29 | 리제너론 파마슈티칼스 인코포레이티드 | 흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 |
| WO2025106736A2 (en) | 2023-11-15 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
| WO2025128836A1 (en) | 2023-12-13 | 2025-06-19 | Eli Lilly And Company | Lag-3 agonist antibodies |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| KR100445103B1 (ko) | 1994-12-09 | 2004-12-04 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의동정 |
| US5939045A (en) | 1994-12-22 | 1999-08-17 | Nissan Chemical Industries, Ltd. | Organic bismuth derivatives for X-ray imaging |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CA2227334A1 (en) | 1995-07-21 | 1997-02-06 | Applied Research Systems Ars Holding N.V. | Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein |
| US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| CA2249998A1 (en) | 1996-03-27 | 1997-10-02 | Crc For Biopharmaceutical Research Pty. Ltd. | The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| US7259247B1 (en) | 1997-09-23 | 2007-08-21 | Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes | Anti-human T-cell costimulating polypeptide monoclonal antibodies |
| KR20010015856A (ko) | 1997-12-12 | 2001-02-26 | 마크로메드 인코퍼레이션 | 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜) |
| CA2320403A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| CA2455365C (en) | 2001-08-03 | 2014-07-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| JP2006523226A (ja) | 2003-02-28 | 2006-10-12 | ザ ジョンズ ホプキンス ユニバーシティ | Ｔ細胞調節方法 |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| SI1729795T1 (sl) | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| AU2005235718B2 (en) | 2004-04-23 | 2011-09-22 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten | Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo |
| KR20070034512A (ko) | 2004-06-18 | 2007-03-28 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
| CA2573745A1 (en) | 2004-07-21 | 2007-01-12 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
| US20060062787A1 (en) | 2004-07-22 | 2006-03-23 | Genentech, Inc. | Method for treating Sjogren's syndrome |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| AU2006270718B2 (en) | 2005-07-22 | 2011-07-21 | Kyowa Kirin Co., Ltd. | Genetically modified antibody composition |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US9585957B2 (en) | 2007-09-07 | 2017-03-07 | The Johns Hopkins University | Adenosine receptor agonists and antagonists to modulate T cell responses |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP2459594A1 (en) | 2009-07-31 | 2012-06-06 | N.V. Organon | Fully human antibodies to btla |
| JP5769316B2 (ja) * | 2009-08-06 | 2015-08-26 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2810465C (en) | 2010-09-16 | 2018-10-02 | Baliopharm Ag | Anti-hutnfr1 antibody |
| WO2013022091A1 (ja) | 2011-08-11 | 2013-02-14 | 小野薬品工業株式会社 | Ｐｄ－１アゴニストからなる自己免疫疾患治療剤 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| SI2970464T1 (sl) | 2013-03-15 | 2020-08-31 | Glaxosmithkline Intellectual Propety Development Limited | Anti-LAG-3 vezavni proteini |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| CN108699145A (zh) * | 2015-09-02 | 2018-10-23 | 伊缪泰普有限公司 | 抗lag-3抗体 |
-
2016
- 2016-09-01 CN CN201680064139.XA patent/CN108699145A/zh active Pending
- 2016-09-01 ES ES16759785T patent/ES2842306T3/es active Active
- 2016-09-01 CA CA2995639A patent/CA2995639A1/en active Pending
- 2016-09-01 CN CN202311238293.2A patent/CN117510633A/zh active Pending
- 2016-09-01 US US15/756,767 patent/US11680104B2/en active Active
- 2016-09-01 KR KR1020257015478A patent/KR20250073532A/ko active Pending
- 2016-09-01 JP JP2018511202A patent/JP7074341B2/ja active Active
- 2016-09-01 EP EP16759785.5A patent/EP3344654B1/en active Active
- 2016-09-01 NZ NZ779096A patent/NZ779096A/en unknown
- 2016-09-01 IL IL257798A patent/IL257798B2/en unknown
- 2016-09-01 DK DK16759785.5T patent/DK3344654T3/da active
- 2016-09-01 WO PCT/EP2016/070664 patent/WO2017037203A1/en not_active Ceased
- 2016-09-01 RU RU2021133819A patent/RU2021133819A/ru unknown
- 2016-09-01 SG SG10201913864RA patent/SG10201913864RA/en unknown
- 2016-09-01 RU RU2018111508A patent/RU2760582C2/ru active
- 2016-09-01 EP EP20197814.5A patent/EP3798234A1/en active Pending
- 2016-09-01 PT PT167597855T patent/PT3344654T/pt unknown
- 2016-09-01 PL PL16759785T patent/PL3344654T3/pl unknown
- 2016-09-01 MX MX2018002610A patent/MX2018002610A/es unknown
- 2016-09-01 KR KR1020187008670A patent/KR102808640B1/ko active Active
- 2016-09-01 MY MYPI2018700711A patent/MY205096A/en unknown
- 2016-09-01 AU AU2016316730A patent/AU2016316730B2/en active Active
-
2018
- 2018-02-19 PH PH12018500369A patent/PH12018500369A1/en unknown
- 2018-03-01 MX MX2023001226A patent/MX2023001226A/es unknown
- 2018-03-01 ZA ZA2018/01432A patent/ZA201801432B/en unknown
-
2021
- 2021-03-15 JP JP2021041608A patent/JP2021097706A/ja active Pending
-
2022
- 2022-07-14 JP JP2022113055A patent/JP2022137218A/ja not_active Withdrawn
-
2023
- 2023-05-05 US US18/312,629 patent/US20230272107A1/en active Pending
- 2023-07-11 AU AU2023204589A patent/AU2023204589A1/en active Pending
-
2024
- 2024-06-07 JP JP2024092967A patent/JP2024116273A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537400A5 (enExample) | ||
| RU2021133819A (ru) | Анти-lag-3 антитела | |
| JP7144477B2 (ja) | 抗ｐｄ－ｌ１抗体 | |
| JP6986965B2 (ja) | 抗ｐｄ−１抗体 | |
| TWI489996B (zh) | Ｃｄ１２７結合蛋白質 | |
| CN109651507B (zh) | 一种激动型4-1bb单克隆抗体 | |
| JP5982409B2 (ja) | Ｃｄ７０に対する抗体 | |
| JP6976322B2 (ja) | 新規抗ｃｔｌａ４抗体 | |
| KR20180030899A (ko) | Pd-l1 (“프로그램화된 사멸-리간드 1”) 항체 | |
| CN113454119B (zh) | 抗btla抗体 | |
| JP2012526558A5 (enExample) | ||
| RU2011145428A (ru) | АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ | |
| AU2017240150A1 (en) | BCMA binding molecules and methods of use thereof | |
| JP2020505386A5 (enExample) | ||
| JP2020502996A5 (enExample) | ||
| JP2012500020A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| TW201538524A (zh) | 特異性結合人ｉｌ－１７ａ的分離的單克隆抗體 | |
| RU2022108410A (ru) | Терапевтические антитела против лиганда cd40 | |
| CN116789820A (zh) | 一种新型免疫调节剂的开发和应用 | |
| WO2022239820A1 (ja) | 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物 | |
| JPWO2020254827A5 (enExample) | ||
| FI4157876T3 (fi) | Anti-pd-1 -vasta-aineita | |
| US20240182594A1 (en) | Uses of antagonist, non-depleting ox40 antibodies | |
| JP2019518473A5 (enExample) |